KRONOS BIO INC. - COM

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

02 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

27 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

13 Oct 2023 12:30:00 By Nasdaq GlobeNewswire

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

04 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

17 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

08 Aug 2023 16:05:03 By Nasdaq GlobeNewswire

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

06 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Upcoming Investor Conferences

01 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

10 May 2023 16:05:02 By Nasdaq GlobeNewswire

Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

24 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Changes to Board of Directors

11 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

15 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference

28 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

09 Jan 2023 07:00:04 By Nasdaq GlobeNewswire

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

11 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

07 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Upcoming Investor Conferences

22 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

08 Nov 2022 16:10:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

08 Nov 2022 16:05:02 By Nasdaq GlobeNewswire